Rhumbline Advisers Buys 5,732 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Rhumbline Advisers boosted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 7.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,923 shares of the company’s stock after purchasing an additional 5,732 shares during the quarter. Rhumbline Advisers owned about 0.12% of Replimune Group worth $764,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its position in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after acquiring an additional 4,975 shares during the period. Clearbridge Investments LLC boosted its position in shares of Replimune Group by 2.7% in the first quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock valued at $2,271,000 after acquiring an additional 7,274 shares during the period. Quest Partners LLC bought a new stake in shares of Replimune Group in the fourth quarter valued at approximately $76,000. Finally, Entropy Technologies LP boosted its position in shares of Replimune Group by 18.3% in the first quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock valued at $485,000 after acquiring an additional 9,180 shares during the period. 92.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Barclays increased their price objective on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. JPMorgan Chase & Co. reduced their target price on Replimune Group from $17.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a research report on Thursday, June 6th. Finally, Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $16.20.

Replimune Group Stock Performance

Replimune Group stock opened at $10.96 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The stock has a fifty day moving average price of $10.28 and a two-hundred day moving average price of $8.45. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.14. The firm has a market capitalization of $673.11 million, a P/E ratio of -3.38 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.10. As a group, analysts anticipate that Replimune Group, Inc. will post -3.08 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.